GLP-1s aren't an easy button. Your strategy shouldn't be, either.

Strategy extends beyond the prescription

GLP-1 therapies require significantly more ongoing management than many ambulatory medications.

Unlike many chronic therapies, successful GLP-1 treatment often requires a comprehensive care model that extends beyond prescribing the medication. Patients achieve better adherence and long-term outcomes when they receive ongoing follow-up, dose titration support, lifestyle counseling, and management from clinicians with expertise in weight management.

For many health systems, that has meant shifting away from viewing GLP-1 therapy as a standalone intervention to integrating pharmacotherapy within a comprehensive weight management program. Instead of asking how to prescribe more efficiently, many are now asking different questions:

• How do we support patients throughout treatment?
• What happens if therapy is interrupted?
• How do we help patients maintain weight loss if medication is eventually discontinued?
• Which disciplines need to be involved throughout the patient's journey?

One of the guiding principles behind a sustainable GLP-1 strategy is resisting the tendency to treat these therapies as a standalone solution, independent of the broader clinical and behavioral support needed for durable outcomes. Long-term success depends on behavioral health, nutrition, exercise, lifestyle modification, and ongoing patient engagement.

That broader perspective becomes increasingly important as questions around duration of therapy continue to evolve. Health systems already are beginning to prepare for conversations with patients about tapering therapy, payer-driven discontinuation, and maintaining outcomes after treatment ends. Helping patients sustain weight loss after medication requires building healthy habits while treatment is ongoing.

Patients also have more options than ever before for accessing GLP-1 therapies. As direct-to-consumer platforms continue to expand, health systems have an opportunity to differentiate themselves by offering coordinated, longitudinal care rather than medication access alone.

Building a program that can scale

Health systems entered the GLP-1 landscape at very different stages of maturity.

Some already had comprehensive weight management programs in place, often supported by pharmacists, dietitians, and behavioral health professionals. Others had established diabetes or endocrine clinics with experience managing these therapies, but fewer resources dedicated to broader multidisciplinary weight management.

Those programs provided a strong foundation, but they didn't necessarily translate into coordinated care across every specialty prescribing GLP-1s. Many early programs were built around a single service line, such as weight management or endocrinology. As cardiology, pulmonology, primary care, and other service lines began incorporating these medications into practice, many health systems found themselves managing multiple independent workflows. That fragmentation affected both operational efficiency and the patient experience.

One of the earliest pressure points was prior authorization. Without a coordinated process, individual service lines often managed authorizations separately, creating inconsistent documentation, limited visibility into approval and denial trends, and duplicated work across specialties. As prescription volume increased, many health systems recognized the value of creating more standardized workflows—whether through centralized prior authorization teams or shared processes that could be applied consistently across service lines.

Medication access, however, represents only one part of the patient journey.

Once therapy begins, patients require regular follow-up to ensure they are titrated safely and consistently toward the most appropriate dose. Those visits also are an opportunity to reinforce the behavioral and lifestyle changes that help maximize the benefits of treatment and improve long-term success.

Rather than focusing solely on medication adjustments, more mature programs integrate nutrition counseling, behavioral health support, exercise guidance, and ongoing patient education into routine follow-up. That holistic approach not only helps patients manage common adverse effects and remain on therapy but also prepares them for future conversations about maintaining weight loss should treatment eventually be tapered or discontinued.

Ultimately, scalability depends on more than seeing additional patients. It requires care models that can deliver consistent, coordinated support throughout the patient's treatment journey, regardless of which specialty initiated therapy.

Designing for sustainability

As patient volumes increase, health systems are balancing finite clinical resources with evolving indications, changing payer requirements, and the need for consistent, long-term follow-up.

But building a sustainable GLP-1 strategy requires workflows that support patients throughout their care journey, including standardized documentation, EHR-based patient registries, structured follow-up schedules, and planned therapy pathways that improve coordination as programs expand.

While GLP-1 programs often are discussed in terms of specialty pharmacy revenue or prescription capture, health systems must also account for the upfront costs of workforce development, pharmacist training, technology infrastructure, and workflow redesign.

Sustainability also requires measuring value over time. Tracking both operational and clinical outcomes helps leaders understand what's working, where additional resources are needed, and how programs should evolve as they mature.

While every health system's approach will differ based on its patient population, resources, and program maturity, several strategies have consistently emerged as foundational to building sustainable GLP-1 programs.

Looking ahead

New indications, changing payer policies, and expanding patient demand will continue to shape how health systems organize care. The organizations that succeed will not necessarily be those prescribing the most GLP-1 therapies. They’ll be those that build scalable stewardship models capable of delivering coordinated, evidence-based weight management care across multiple specialties while continuously measuring outcomes and adapting as evidence evolves.